Shadia I. Jalal
0000-0001-8938-7077
Publication & Citation Trends
Most Cited Works
Publications
245 total
HSR26-258: Patient-Level Impact of the 2023 Platinum Chemotherapy Shortage on Access of Treatment in Lung Cancer
Cited by 0
Semantic Scholar
Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs.
Cited by 0
Semantic Scholar
Abstract 236: Targeting DNA damage sensors (DDS) to enhance Osimertinib response in EGFR-driven cancers.
Cited by 0
Semantic Scholar
HSR26-193: Integrating Print-to-Web Outreach into Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study
Cited by 0
Semantic Scholar
Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer
Cited by 0
Semantic Scholar
Potentiation of EGFR mutant lung cancer treatment targeting replication stress
Cited by 0
Semantic Scholar
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
Cited by 2
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(60)
Cancer Immunotherapy and Biomarkers
(56)
Lung Cancer Research Studies
(52)
Esophageal Cancer Research and Treatment
(29)
Lung Cancer Diagnosis and Treatment
(28)
Frequent Co-Authors
Affiliations
University of Maryland, Baltimore
Indiana University Health
Merck & Co., Inc., Rahway, NJ, USA (United States)
University of Indianapolis
National University of Singapore